Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy

•The incidence rates of low-level viremia (LLV) (plasma HIV RNA load of 50–999 copies/mL) and virologic failure (VF) (plasma HIV RNA load ≥1000 copies/mL) were low after the switch to co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF) in people living with HIV-1 who had been receiving suppressive antiretroviral therapy.•LLV before and after the switch to EVG/c/FTC/TAF and prior exposure to integrase inhibitor-based regimens were associated with occurrences of LLV during the follow-up.•VF was associated with LLV before and after the switch to EVG/c/FTC/TAF and prior exposure to raltegravir. We aimed to investigate the incidence of low-level viremia (LLV) and its impact on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy (ART) who switched to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/c/FTC/TAF). PLWH aged 18 years or older who had received ART with plasma HIV RNA load (PVL)